Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.
Agios Pharmaceuticals Inc. (NASDAQ: AGIO) shares declined 8.77 percent to close at $29.11 a share Monday. The stock traded between $29.04 and $32.35 on volume of 163,562 shares traded. Analysts at JPMorgan have recently initiated coverage on the company with a “neutral” rating. Shares of Agios Pharmaceuticals have fallen approximately 7.0 percent year-to-date.
Find out more about Agios Pharmaceuticals including full access to the free equity report at:
Huntsman Corporation (NYSE: HUN) shares declined 0.62 percent to close at $17.71 a share Monday. The stock traded between $17.66 and $18.06 on volume of 1.62 million shares traded. Analysts at Macquarie have recently upgraded the company’s rating to “outperform” and currently have a price target of $21.00 on the stock. Shares of Huntsman have gained approximately 11.0 percent year-to-date.
Find out more about Huntsman including full access to the free equity report at:
Kaiser Aluminum Corp. (NASDAQ: KALU) shares increased 2.12 percent to close at $68.75 a share Monday. The stock traded between $67.60 and $69.22 on volume of 292,242 shares traded. Analysts at Sterne Agee have recently upgraded the company’s rating to “buy” from “neutral”. Shares of Kaiser Aluminum have gained approximately 11.0 percent year-to-date.
Find out more about Kaiser Aluminum including full access to the free equity report at:
Onconova Therapeutics Inc. (NASDAQ: ONTX) shares declined 4.98 percent to close at $24.41 a share Monday. The stock traded between $23.91 and $26.00 on volume of 199,803 shares traded. Analysts at Leerink have recently initiated coverage on the company with an “outperform” rating and a price target of $37.00. Shares of Onconova Therapeutics have gained approximately 22.0 percent year-to-date.
Find out more about Onconova Therapeutics including full access to the free equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Research Driven Investing
Leave a comment...